Skyhawk Therapeutics publica los resultados de doce meses del subcomponente cUHDRS

Phase 1positiveSKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics announced 12-month results from its Phase 1/2 trial of SKY-0515 in Huntington's disease, showing favorable and consistent trends in the cUHDRS subcomponent for treated participants.

Clinical Trial Data

Phase

1/2

Primary Endpoint

Met

Outcome Details

12-month results showed favorable and consistent trends in cUHDRS subcomponent for SKY-0515 recipients

Importance:6/10

Sentiment:

0.70

Huntington's diseasePhase 1/2 trialclinical dataneurology

Read the original article

Published by PR Newswire Clinical Trials on June 30, 2026 4:51 PM

Read Original